Sarepta Therapeutics, Inc. (SRPT)
-NasdaqGM | Prev Close: | 32.59 |
|---|
| Open: | N/A |
|---|
| Bid: | N/A |
|---|
| Ask: | N/A |
|---|
| 1y Target Est: | 46.33 |
|---|
| Beta: | 0.98 |
|---|
| Next Earnings Date: | 9-May-13 |
|---|
| Day's Range: | N/A - N/A |
|---|
| 52wk Range: | 3.30 - 45.00 |
|---|
| Volume: | 0 |
|---|
| Avg Vol (3m): | 1,929,350 |
|---|
| Market Cap: | 1.04B |
|---|
| P/E (ttm): | N/A |
|---|
| EPS (ttm): | -5.14 |
|---|
| Div & Yield: | N/A (N/A) |
|---|
The broker you select will become the default broker for Trade Now
Quotes delayed, except where indicated otherwise. Currency in USD.
Headlines
- 3 Biggest Biotech Crashes in Aprilat Motley Fool(Thu, May 2)
- Sarepta Therapeutics Inc (SRPT): Today's Featured Drugs Winnerat TheStreet(Wed, May 1)
- Sarepta (SRPT) Targets Unmet Medical Need in the Treatment of Duchenne Muscular Dystrophy; Developing First Drug with the Promise of Stopping Fatal Progressive DiseaseWall Street Transcript(Mon, Apr 29)
- NewLink Genetics: Looking To Join The Industry's Largest Moversat Seeking Alpha(Mon, Apr 29)
- Sarepta Therapeutics to Announce First Quarter 2013 Financial Results and Corporate Update on May 9, 2013Marketwired(Fri, Apr 26)
- Biotech Stock Mailbag: ASCO, Sarepta, Cel-Sci and Hate Mail!at TheStreet(Fri, Apr 26)
- Sarepta: Staying Long and Strongat TheStreet(Thu, Apr 25)
- When Twitter Rogues Move Markets: A Timelineat BusinessWeek(Thu, Apr 25)
- Sarepta Therapeutics: Irrational Exuberanceat Seeking Alpha(Thu, Apr 25)
- Quickly Approaching Biopharma Catalyst Eventsat Seeking Alpha(Wed, Apr 24)
- A Biotech Firm's Ultimate Decision: To Finance, To Find A Partner Or To Go Bankruptat Seeking Alpha(Tue, Apr 23)
- Are These Billion-Dollar Biotechs Overvalued?at Motley Fool(Tue, Apr 23)
- Analyzing Market Efficiency: Why Future Catalysts Imply Sanuwave Still Has Room To Doubleat Seeking Alpha(Tue, Apr 23)
- 5 Hot Stocks: Facebook’s Home Fails To Dazzle, Check Point’s Lukewarm Earnings, and Six Flags Sets A Recordat Wall St. Cheat Sheet(Mon, Apr 22)
- Want to Invest in Biotech? Think Like a Venture Capitalistat Motley Fool(Mon, Apr 22)
Key Statistics
| Forward P/E (1 yr): | N/A |
|---|
| P/S (ttm): | 27.79 |
|---|
| Ex-Dividend Date: | N/A |
|---|
Analysts
| Annual EPS Est
(Dec-13)
: | -2.90 |
|---|
| Quarterly EPS Est
(Mar-13)
: | -0.62 |
|---|
| Mean Recommendation*: | 1.8 |
|---|
| PEG Ratio (5 yr expected): | -0.51 |
|---|
Business Summary
Sarepta Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery and development of RNA-based therapeutics for the treatment of rare and infectious diseases.
View More